Matcheri Keshavan, MD

Dr. Keshavan is Stanley Cobb Professor of Psychiatry at the Beth Israel Deaconess Medical Center; Harvard Medical School, a position he assumed in April 2008. He is also Academic Head for the department. . Dr. Keshavan received his medical training in Mysore, India (where he graduated at the top of his University), and his psychiatric training in Bangalore (India), Vienna, London, and Detroit.

Dr. Keshavan is closely involved in research in neurobiology of psychosis, especially as it pertains to first episode psychotic disorders. His research has resulted in over 700 publications to date, including over 700 peer-reviewed papers, 4 books, and 100 reviews/ book chapters. He has received several awards including the Gaskell Gold Medal of the Royal College of Psychiatrists (1985); Nancy Roschke Certificate for Teaching Excellence of the American Psychiatric Association in 1993; Teaching awards at the Departments of Psychiatry in Pittsburgh (1992, 1994, and 2004), Wayne State University (2008) and at Harvard (2011); the Research Scientist Development Award from NIMH (National Institute of Mental Health); the 2003 NAMI (National Alliance for the Mentally Ill) of Pennsylvania Psychiatrist of the Year Award and the 2013 Gerard Hogarty Award for Research from the University of Pittsburgh. He is a distinguished Fellow of the American Psychiatric Association; a Fellow of the Royal College of Physicians, Canada; and a Fellow of the Royal College of Psychiatrists, UK.

Dr. Keshavan is the Editor-in-Chief of the Schizophrenia Research (Elsevier) and serves on the editorial board for journals such as Early Intervention in Psychiatry, and Asian J Psychiatry. In addition, Dr. Keshavan is often invited to speak at national and international conferences. He has several funded grants. His main areas of research include the neurodevelopmental basis of schizophrenia, neuroimaging, and early intervention.

For list of publications, see

Matcheri Keshavan | Harvard Catalyst Profiles | Harvard Catalyst

Papers relevant to SDoH:

Michaels TI, Carrión RE, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Walker EF, Woods SW, Cornblatt BA. Ethnoracial discrimination and the development of suspiciousness symptoms in individuals at clinical high-risk for psychosis. Schizophr Res. 2023 Feb 27;254:125-132. doi: 10.1016/j.schres.2023.02.021. Epub ahead of print. PMID: 36857950.

Bondre AP, Shrivastava R, Raghuram H, Tugnawat D, Khan A, Gupta S, Kumar M, Mehta UM, Keshavan M, Lakhtakia T, Chand PK, Thirthalli J, Patel V, Torous J, Rozatkar AR, Naslund JA, Bhan A. A qualitative exploration of perceived needs and barriers of individuals with schizophrenia, caregivers and clinicians in using mental health applications in Madhya Pradesh, India. SSM Ment Health. 2022 Dec;2:100063. doi: 10.1016/j.ssmmh.2022.100063. PMID: 36688236; PMCID: PMC9792372.

D’Souza DC, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World J Biol Psychiatry. 2022 Dec;23(10):719-742. doi: 10.1080/15622975.2022.2038797. Epub 2022 Mar 22. PMID: 35315315.

Barbato M, Liu L, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone W, Tsuang MT, Walker EF, Woods SW, Cannon TD, Addington J. Migrant status, clinical symptoms and functional outcome in youth at clinical high risk for psychosis: findings from the NAPLS-3 study. Soc Psychiatry Psychiatr Epidemiol. 2022 Nov 8. doi: 10.1007/s00127-022-02383-y. Epub ahead of print. PMID: 36348056.

Farris MS, Braun A, Liu L, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Stone WS, Tsuang MT, Walker EF, Woods SW, Cannon TD, Addington J. Longitudinal impact of trauma in the North American Prodrome Longitudinal Study-3. Early Interv Psychiatry. 2022 Nov;16(11):1211-1216. doi: 10.1111/eip.13270. Epub 2022 Feb 13. PMID: 35152553; PMCID: PMC9374846.

Santesteban-Echarri O, Liu L, Miller M, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Walker EF, Woods SW, Addington J. Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis. Schizophr Res. 2022 Oct;248:114-121. doi: 10.1016/j.schres.2022.08.005. Epub 2022 Aug 26. PMID: 36030758.

Braun A, Liu L, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone W, Tsuang MT, Walker EF, Woods SW, Cannon TD, Addington J. Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort. Soc Psychiatry Psychiatr Epidemiol. 2022 Jul;57(7):1379-1388. doi: 10.1007/s00127-022-02239-5. Epub 2022 Feb 3. PMID: 35113189.

Davis B, Anglin DM, Oluwoye O, Keshavan M. The unfulfilled promise of equitable first episode care for Black-Americans: A way forward. Schizophr Res. 2022 Mar;241:171-173. doi: 10.1016/j.schres.2022.01.046. Epub 2022 Feb 3. PMID: 35124436; PMCID: PMC9158457.

Ku BS, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Compton MT, Cornblatt BA, Druss BG, Keshavan M, Mathalon DH, Perkins DO, Stone WS, Tsuang MT, Woods SW, Walker EF. The associations between area-level residential instability and gray matter volumes from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophr Res. 2022 Mar;241:1-9. doi: 10.1016/j.schres.2021.12.050. Epub 2022 Jan 20. PMID: 35066429; PMCID: PMC8960350.

Kline ER, Ferrara M, Li F, D’Souza DC, Keshavan M, Srihari VH. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. J Psychiatr Res. 2022 Mar;147:248-253. doi: 10.1016/j.jpsychires.2022.01.039. Epub 2022 Jan 16. PMID: 35066293; PMCID: PMC8882157.

Ku BS, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Compton MT, Cornblatt BA, Keshavan M, Mathalon DH, Perkins DO, Stone WS, Tsuang MT, Walker EF, Woods SW, Druss BG. Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophr Res. 2021 Dec;238:137-144. doi: 10.1016/j.schres.2021.09.025. Epub 2021 Oct 19. PMID: 34673386.

Velikonja T, Velthorst E, Zinberg J, Cannon TD, Cornblatt BA, Perkins DO, Cadenhead KS, Tsuang MT, Addington J, Woods SW, McGlashan T, Mathalon DH, Stone W, Keshavan M, Seidman L, Bearden CE. Childhood trauma and cognitive functioning in individuals at clinical high risk (CHR) for psychosis. Dev Psychopathol. 2021 Feb;33(1):53-64. doi: 10.1017/S095457941900155X. PMID: 31959269.

Abush H, Ghose S, Van Enkevort EA, Clementz BA, Pearlson GD, Sweeney JA, Keshavan MS, Tamminga CA, Ivleva EI. Associations between adolescent cannabis use and brain structure in psychosis. Psychiatry Res Neuroimaging. 2018 Jun 30;276:53-64. doi: 10.1016/j.pscychresns.2018.03.008. Epub 2018 Mar 28. PMID: 29628270; PMCID: PMC5959798.

Padmanabhan JL, Shah JL, Tandon N, Keshavan MS. The “polyenviromic risk score”: Aggregating environmental risk factors predicts conversion to psychosis in familial high-risk subjects. Schizophr Res. 2017 Mar;181:17-22. doi: 10.1016/j.schres.2016.10.014. Epub 2016 Oct 29. PMID: 28029515; PMCID: PMC5365360.

Torous J, Keshavan M. The role of social media in schizophrenia: evaluating risks, benefits, and potential. Curr Opin Psychiatry. 2016 May;29(3):190-5. doi: 10.1097/YCO.0000000000000246. PMID: 26967314.